Summary
January 2010, Vol. 40, No. 1, Pages 24-37 , DOI 10.3109/00498250903351013

Validation of cell-based OATP1B1 assays to assess drug transport and the potential for drug–drug interaction to support regulatory submissions

P. Sharma, V. E. Holmes, R. Elsby, C. Lambert, D. Surry
Clinical Pharmacology & DMPK, AstraZeneca R&D Charnwood, Loughborough, UK
Address for Correspondence:Pradeep Sharma, Clinical Pharmacology & DMPK, AstraZeneca R&D Charnwood, Bakewell Road, Loughborough LE11 5RH, UK. E-mail:



  1. Transporters are carrier proteins that may influence pharmacokinetic, pharmacodynamic, and toxicological characteristics of drugs. The development of validated in vitro transporter models is imperative to support regulatory submissions of drug candidates. This study is focused on utilizing human embryonic kidney (HEK) 293 cell cultures genetically transfected with the human organic anion transporting polypeptides (OATP) 1B1 transporter to identify substrates and inhibitors in drug development.

  2. The kinetics of OATP1B1-mediated uptake of [3H]-oestradiol 17β-glucuronide and inhibition of uptake by rifamycin SV were used to determine Km, Vmax, and IC50 values over a range of passage numbers to investigate accuracy and precision. The mean Km and Vmax values were found to be 6.3±1.2 μM and 460±96 pmol min−1 mg−1, respectively. The mean IC50 value for rifamycin SV was 0.23±0.07 μM on uptake of 1 μM [3H]-oestradiol 17β-glucuronide. These data were similar to previously reported values (accuracy greater than 82%), reproducible (precision less than 29%) and exhibited low standard deviations (SDs) obviating the need to study test compounds on more than one occasion.

  3. [3H]-oestrone 3-sulfate and [3H]-pravastatin exhibited concentration-dependent OATP1B1 uptake, and statistically significant differences were observed at each concentration between uptake rates of HEK293-OATP1B1 and HEK293-MOCK cells (uptake ratios greater than or equal to 3). Propranolol showed no positive uptake ratio. Bezafibrate and gemfibrozil exhibited concentration-dependent inhibition of OATP1B1-mediated uptake of [3H]-oestradiol 17β-glucuronide with mean IC50 values of 16 and 27 μM, respectively.

  4. Based on the validation results, acceptance criteria to identify a test compound as a substrate and/or inhibitor using these specific cell lines were determined. These validated OATP1B1 assays were robust, reproducible, and suitable for routine in vitro evaluation of candidate drugs.

Full Text | PDF (838 KB) | PDF Plus (872 KB)


Users who read this article also read:

Effects of organic solvents on the time-dependent inhibition of CYP3A4 by diazepam
Y. Nishiya, K. Nakamura, N. Okudaira, K. Abe, N. Kobayashi, O. Okazaki
Xenobiotica, Jan 2010, Vol. 40, No. 1, Pages 1-8.
Summary | Full Text | PDF (849 KB) | PDF Plus (863 KB) | Add to Favorites | Related 
In vitro evidence for the formation of reactive intermediates of resveratrol in human liver microsomes
R. C. Steenwyk, B. Tan
Xenobiotica, Jan 2010, Vol. 40, No. 1, Pages 62-71.
Summary | Full Text | PDF (1063 KB) | PDF Plus (1073 KB) | Add to Favorites | Related 
Integrated HPLC-MS and 1H-NMR spectroscopic studies on acyl migration reaction kinetics of model drug ester glucuronides
C. H. Johnson, E. Karlsson, S. Sarda, L. Iddon, M. Iqbal, X. Meng, J. R. Harding, A. V. Stachulski, J. K. Nicholson, I. D. Wilson, J. C. Lindon
Xenobiotica, Jan 2010, Vol. 40, No. 1, Pages 9-23.
Summary | Full Text | PDF (1064 KB) | PDF Plus (1091 KB) | Add to Favorites | Related 
In vitro evidence for the role of OATP and OCT uptake transporters in drug–drug interactions
Jürgen Kindla, Martin F Fromm, Jörg König
Expert Opinion on Drug Metabolism & Toxicology, May 2009, Vol. 5, No. 5, Pages 489-500.
Summary | Full Text | PDF (455 KB) | PDF Plus (520 KB) | Add to Favorites | Related 
In vitro model for the prediction of clinical CYP3A4 induction using HepaRG cells
A. Kaneko, M. Kato, N. Sekiguchi, T. Mitsui, K. Takeda, Y. Aso
Xenobiotica, Nov 2009, Vol. 39, No. 11, Pages 803-810.
Summary | Full Text | PDF (853 KB) | PDF Plus (854 KB) | Add to Favorites | Related 
Comparison of mechanism-based inhibition of human cytochrome P450 2C19 by ticlopidine, clopidogrel, and prasugrel
Y. Nishiya, K. Hagihara, A. Kurihara, N. Okudaira, N.A. Farid, O. Okazaki, T. Ikeda
Xenobiotica, Nov 2009, Vol. 39, No. 11, Pages 836-843.
Summary | Full Text | PDF (948 KB) | PDF Plus (949 KB) | Add to Favorites | Related 
 

Prev. Article | Next Article
View/Print PDF (838 KB)
View PDF Plus (872 KB)
Add to favourite
Email to a friend
TOC Alert | Citation Alert What is RSS?

 
 
Quick Search
for 
Authors:
P. Sharma
V. E. Holmes
R. Elsby
C. Lambert
D. Surry
Keywords:
OATP1B1
validation
in vitro
regulatory
US Food and Drug Administration (US FDA)
transporters